Biopharma Daily Stock Updates - 06/14/22

Table of Contents:

#

#OTLK +16% Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010.

#CLVS +15.7% Clovis Oncology Highlights Phase 1 Data From Ongoing Clinical Studies Of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting

#MOR -1.5% (+14.7% Aftr mrkt) MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210

#HRTX +3.5% Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty.

#SRNE +1.4% Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.

#LPCN -1.2% LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS.

#FUSN -4.1% Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434

#PCRX -5.8% Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $46.0 Million for May 2022.

Want to get weekly catalyst updates?

*We never spam you - unsubscribe anytime*

#DAWN +5.8% Day One Announces Proposed Public Offering of Common Stock.

#COGT +3.7% Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants.

#WVE -4.5% Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering.

Posted by FS/JM